Loading…
Rocket Pharmaceuticals, Inc. is projected to rise to $4.00 by 2027, a +1% move from its current price of $3.95. RCKT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $3.81 | $3.95 | $4.10 | -0.02% |
| Jul 13 | $3.75 | $3.95 | $4.16 | -0.03% |
| Jul 14 | $3.71 | $3.95 | $4.20 | -0.05% |
| Jul 15 | $3.67 | $3.95 | $4.24 | -0.06% |
| Jul 16 | $3.64 | $3.95 | $4.28 | -0.08% |
| Jul 17 | $3.61 | $3.95 | $4.31 | -0.09% |
| Jul 18 | $3.58 | $3.95 | $4.34 | -0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.58 | $3.95 | $4.34 | -0.11% |
| Week 2 | $3.44 | $3.94 | $4.51 | -0.22% |
| Week 3 | $3.33 | $3.94 | $4.65 | -0.32% |
| Week 4 | $3.25 | $3.93 | $4.77 | -0.43% |
| Week 5 | $3.17 | $3.93 | $4.87 | -0.54% |
| Week 6 | $3.10 | $3.92 | $4.96 | -0.65% |
| Week 7 | $3.04 | $3.92 | $5.05 | -0.75% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (RP-A501), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is in preclinical stage.
It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).
It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Rocket Pharmaceuticals, Inc. trades under the ticker RCKT in the Healthcare sector. It currently changes hands at $4.24 and has a market capitalization of $462.98M, with a market rank of 3104.
The near-term price outlook is mixed, but the long-run view shows a bullish trajectory per the provided forecast data. The stock’s current price sits near notable technical levels, with a 30-day range expressed by the forecast data.
A major floor 50.8% below — a decisive break under it would weaken the trend.
The nearest floor, 34.2% below — buyers have tended to step in here.
The nearest ceiling, 7.3% above — a clean break opens room to run.
A major ceiling 34.2% above — clearing it would confirm fresh momentum.
Key RCKT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCKT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.08 | Sell | $3.99 | Sell |
| MA 10 | $3.78 | Buy | $3.83 | Buy |
| MA 20 | $3.44 | Buy | $3.58 | Buy |
| MA 50 | $3.29 | Buy | $3.44 | Buy |
| MA 100 | $3.70 | Buy | $3.52 | Buy |
| MA 200 | $3.57 | Buy | $4.02 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.83 | Neutral |
| Stoch RSI (14) | 36.59 | Neutral |
| CCI (20) | 84.06 | Neutral |
| Williams %R (14) | -33.00 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 12.68 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 67.00 | Neutral |
| TRIX (15) | 0.75 | Buy |
| Awesome (5,34) | 0.86 | Buy |
| Ultimate (7,14,28) | 68.88 | Neutral |
| Momentum (10) | 0.67 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 4.27 | Sell |
| ADX (14) | 30.38 | Buy |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 80. The price is above the SMA50 of $3.27 and near the SMA200 of $3.57, suggesting cautious upside potential but at risk of near-term resistance.
The 30-day range spans from $3.35 to $5.36, indicating noticeable volatility within the period. Near-term support is listed at $2.60 and resistance at $4.24, framing a cautious outlook.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.60 | $3.95 | $4.79 | 0% | Neutral | |
| $3.09 | $4.00 | $5.54 | +1% | Neutral | |
| $2.85 | $3.84 | $5.58 | -3% | Neutral | |
| $3.13 | $4.35 | $6.55 | +10% | Neutral | |
| $3.99 | $5.71 | $8.86 | +45% | Bullish | |
| $3.87 | $5.68 | $9.05 | +44% | Bullish | |
| $3.98 | $6.00 | $9.78 | +52% | Bullish | |
| $4.19 | $6.46 | $10.77 | +64% | Bullish | |
| $3.73 | $5.87 | $9.98 | +49% | Bullish | |
| $3.80 | $6.12 | $10.59 | +55% | Bullish | |
| $5.19 | $9.23 | $17.20 | +134% | Bullish | |
| $7.52 | $16.01 | $33.22 | +305% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.60 | $3.95 | $4.67 | +0.00% |
| August 2026 | $3.18 | $3.78 | $4.65 | -4.24% |
| September 2026 | $3.24 | $3.89 | $4.86 | +2.97% |
| October 2026 | $3.27 | $3.96 | $5.01 | +1.77% |
| November 2026 | $3.12 | $3.80 | $4.85 | -4.08% |
| December 2026 | $3.03 | $3.72 | $4.79 | -2.21% |
Click any year to see its month-by-month RCKT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RCKT is projected to trade between $2.60 and $4.79, averaging $3.95 — a potential gain of 0% from today's $3.95. A consolidation phase looks the most probable path here.
Rocket Pharmaceuticals, Inc.'s 2027 outlook centres on $4.00, within a $3.09 to $5.54 range. That is up +1% on the projected 2026 average. That marks a +1% change versus current levels. Price action looks broadly range-bound.
By 2028, RCKT could reach as high as $5.58, with a base case around $3.84 and support toward $2.85 — roughly -3% from $3.95. A consolidation phase looks the most probable path here.
Expect RCKT to range from $3.13 to $6.55 through 2029. The $4.35 average target implies a +10% move from current prices. That is up +13% on the projected 2028 average. Price action looks broadly range-bound.
The RCKT price prediction for 2030 points to an average of $5.71 (low $3.99, high $8.86) — a potential gain of +45% on today's $3.95. Buyers look set to stay in control over this stretch.
In 2031, RCKT is projected to trade between $3.87 and $9.05, averaging $5.68 — a potential gain of +44% from today's $3.95. That is -1% versus the projected 2030 average. Momentum favours further upside here.
Rocket Pharmaceuticals, Inc.'s 2032 outlook centres on $6.00, within a $3.98 to $9.78 range. That is up +6% on the projected 2031 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, RCKT could reach as high as $10.77, with a base case around $6.46 and support toward $4.19 — roughly +64% from $3.95. Momentum favours further upside here.
Expect RCKT to range from $3.73 to $9.98 through 2034. The $5.87 average target implies a +49% move from current prices. That is -9% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The RCKT price prediction for 2035 points to an average of $6.12 (low $3.80, high $10.59) — a potential gain of +55% on today's $3.95. Momentum favours further upside here.
In 2040, RCKT is projected to trade between $5.19 and $17.20, averaging $9.23 — a potential gain of +134% from today's $3.95. That is up +51% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Rocket Pharmaceuticals, Inc.'s 2050 outlook centres on $16.01, within a $7.52 to $33.22 range. That is up +73% on the projected 2040 average. That marks a +305% change versus current levels. Momentum favours further upside here.
Investing $1,000 in RCKT today (≈ 253.164557 RCKT) could be worth
$4,053.3
+$3,053.3 (+305%) by 2050 · US Dollar
Based on the average projected RCKT price of $16.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCKTwould be worth at today's price.
$1,000 invested in RCKT on Jul 10, 2025 (≈ 316.455688 RCKT) would be worth
$1,250
+$250 (+25.0%) today · 1.25× · US Dollar
Based on a RCKT entry price of $3.16 vs. today's $3.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.84 | $1,028.65 | +2.9% |
| 1 month ago | $2.6 | $1,519.23 | +51.9% |
| 3 months ago | $3.49 | $1,131.81 | +13.2% |
| 6 months ago | $3.6 | $1,097.22 | +9.7% |
| 1 year ago | $3.16 | $1,250 | +25.0% |
| All time (5.0y) ago | $46.47 | $85 | -91.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCKT forecast.
Our base-case forecast reaches $7.90 around 2040.
Implied market cap at $7.90: $862.63M
The multi-year forecast shows a bullish trajectory beyond 2026, with annualized upside reflected in the Avg prices and ROIs for key years.
For 2030, the avg is $6.82 with a 60.8% ROI, and the 2050 forecast shows an avg of $21.84 with a 415.1% ROI. Key mid-term milestones include 2040 with an avg of $11.76 and a 177.4% ROI. Sentiment transitions from Neutral in the near term to Bullish across 2029–2050, reflecting a higher expected valuation as the pipeline and programs mature.
Volatility is high, with annualized volatility at 70%.
These figures are estimates of future performance and are not guaranteed; actual results may differ due to market and clinical development dynamics.
Tap a question to reveal the answer.
2030 min $4.79, avg $6.82, max $10.53, ROI 60.8%, sentiment BULLISH.
Forecasts show a bullish trajectory beyond 2026 with rising averages and ROI, including 2030 avg $6.82 (ROI 60.8%), 2040 avg $11.76 (ROI 177.4%), and 2050 avg $21.84 (ROI 415.1%), though results are not guaranteed.
According to the forecast, the max by 2050 is $44.94, so $50 is above the forecasted maximum.
Current price is $4.24 and market cap is $462.98M.
RSI14 is 80; SMA50 is $3.27; SMA200 is $3.57; 30-day range is $3.35 to $5.36; support is $2.60 and resistance is $4.24.
Rocket Pharmaceuticals, Inc. Community Discussion
0Share your Rocket Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.